Find A Clinical Trial
Disease Type: Lymphoma
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362)
A Multicenter, Open-Label, First-in-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-Cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-Cancer Agents in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma
A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkins Lymphoma and CD30-expressing Peripheral T-Cell Lymphoma (PTCL) in Older Patients or Patients with Significant Comorbidities Ineligible for Standard Therapy
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-Intermediate and High-Risk Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
A Phase 3, Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma
Phase 3 Double-Blind, Active Controlled, 3-Stage Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma.
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)